Core A: Pathobiology Core
核心 A:病理生物学核心
基本信息
- 批准号:10612365
- 负责人:
- 金额:$ 40.87万
- 依托单位:
- 依托单位国家:美国
- 项目类别:
- 财政年份:2022
- 资助国家:美国
- 起止时间:2022-05-01 至 2027-04-30
- 项目状态:未结题
- 来源:
- 关键词:3-DimensionalAntibodiesBiological AssayBiopsy SpecimenCastrationCellsClinicalCollaborationsCollectionComplexComputing MethodologiesDataDevelopmentDiseaseDisease ResistanceEpitheliumEvaluationFreezingGenerationsGeneticGenetic RecombinationGenetically Engineered MouseGenotypeGoalsHumanImageImmuneImmunofluorescence ImmunologicIn SituInflammatory InfiltrateLinkMalignant NeoplasmsMalignant neoplasm of prostateMetastatic Neoplasm to the BoneMicroscopicModalityModelingMolecularMolecular AnalysisMusNeoplasm MetastasisNeuroendocrine TumorsOrganoidsOutcomeParaffin TissuePathologicPathologyPatientsPerformancePhenotypeProstateProstaticProteinsRadical ProstatectomyResearch PersonnelResearch Project GrantsResistanceResourcesRoleSamplingSeriesServicesSignal TransductionSliceSpecimenStainsSystems AnalysisTechniquesTechnologyTissue MicroarrayTissue SampleTissue imagingTissuesValidationarmbonecellular imagingexperimental studygene discoveryhuman tissueimaging platformimprovedin situ imaginginnovationlaser capture microdissectionmolecular pathologymouse modelmultidisciplinaryneoplastic cellnew technologynovelnovel strategiesnucleic acid quantitationprogramssingle cell analysissingle cell sequencingsingle-cell RNA sequencingsuccesstherapy resistanttooltranscriptomicstumortumor heterogeneitytumor progression
项目摘要
Project Summary/Abstract
Cancer is a highly heterogenous disease, composed of and characterized by a diverse set of genetic
phenotypes driven by complex dynamic cellular interactions within spatially distinct organized
microenvironments. The ability to accurately delineate this intra tumor heterogeneity and its contribution to
metastasis, therapeutic resistance and ultimately the impact of clinical outcomes, remains a challenge. In
addition, the molecular mechanisms underpinning the cross-talk between tumor and its microenvironment are
largely lacking.
This prostate cancer Program Project sets out to investigate the tumor cell intrinsic as well as stromal
and immune microenvironmental factors in tumor progression using single cell sequencing technologies.
Additionally, the Program will incorporate a multi-disciplinary and integratory approach that aims to integrate
single-cell RNA-sequencing and systems analyses of genetically engineered mouse and organoid models, with
complementary analyses of human tissue samples in naïve, castration-resistant and neuroendocrine tumors,
both local and metastatic.
The Pathobiology Core (Core A) will support the projects by providing expert histopathologic analysis of
murine and human tumors, validating antibodies and probes for use in mouse and human tissue, comparing and
contrasting multiple signals in epithelium and microenvironment in mouse models and patient samples.
Innovative approaches including organotypic cultures and recombination experiments will be utilized as
functional assays. Finally, refining strategies in computational methods to compare single cell analyses in human
and mouse as well as developing novel approaches to improve and automate in situ expression modalities will
represent the innovation arm of this core.
项目总结/摘要
癌症是一种高度异质性的疾病,由一组不同的遗传因子组成并以其为特征。
表型由空间上不同组织的复杂动态细胞相互作用驱动
微环境准确描述这种肿瘤内异质性的能力及其对
转移、治疗耐药性以及最终对临床结果的影响仍然是一个挑战。在
此外,肿瘤与其微环境之间相互作用的分子机制是
大部分缺乏。
这个前列腺癌计划项目着手研究肿瘤细胞内在以及间质
和免疫微环境因素在肿瘤进展中的作用。
此外,该计划将采用多学科和整合的方法,旨在整合
基因工程小鼠和类器官模型的单细胞RNA测序和系统分析,
对初治、去势抵抗和神经内分泌肿瘤的人体组织样本进行补充分析,
包括局部和转移性。
病理生物学核心(核心A)将通过提供以下方面的专家组织病理学分析来支持这些项目:
小鼠和人肿瘤,验证用于小鼠和人组织的抗体和探针,比较和
对比小鼠模型和患者样品中上皮和微环境中的多种信号。
创新的方法,包括器官型培养和重组实验将被利用,
功能测定最后,改进计算方法中的策略以比较人类单细胞分析,
以及开发新的方法来改善和自动化原位表达模式,
代表了这个核心的创新力量。
项目成果
期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)
数据更新时间:{{ journalArticles.updateTime }}
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
数据更新时间:{{ journalArticles.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ monograph.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ sciAawards.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ conferencePapers.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ patent.updateTime }}
Massimo Loda其他文献
Massimo Loda的其他文献
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
{{ truncateString('Massimo Loda', 18)}}的其他基金
Weill Cornell Medicine (WCM) SPORE in Prostate Cancer
威尔康奈尔医学 (WCM) 孢子在前列腺癌中的应用
- 批准号:
10227725 - 财政年份:2017
- 资助金额:
$ 40.87万 - 项目类别:
Weill Cornell Medicine (WCM) SPORE in Prostate Cancer
威尔康奈尔医学 (WCM) 孢子在前列腺癌中的应用
- 批准号:
9763515 - 财政年份:2017
- 资助金额:
$ 40.87万 - 项目类别:
Targeting the p110beta isoform of PI3 kinase in prostate cancer
靶向前列腺癌中 PI3 激酶的 p110beta 亚型
- 批准号:
9248261 - 财政年份:2015
- 资助金额:
$ 40.87万 - 项目类别:
Targeting the p110beta isoform of PI3 kinase in prostate cancer
靶向前列腺癌中 PI3 激酶的 p110beta 亚型
- 批准号:
9036357 - 财政年份:2015
- 资助金额:
$ 40.87万 - 项目类别:
Targeting the p110beta isoform of PI3 kinase in prostate cancer
靶向前列腺癌中 PI3 激酶的 p110beta 亚型
- 批准号:
8886182 - 财政年份:2015
- 资助金额:
$ 40.87万 - 项目类别:
PALMITOYLATION SIGNATURE IN PROSTATE CANCER CELL LINES
前列腺癌细胞系中的棕榈酰化特征
- 批准号:
8171371 - 财政年份:2010
- 资助金额:
$ 40.87万 - 项目类别:
Metabolic Syndrome, Fatty Acid Synthesis and Prostate Cancer
代谢综合征、脂肪酸合成和前列腺癌
- 批准号:
7915834 - 财政年份:2009
- 资助金额:
$ 40.87万 - 项目类别:
Metabolic Syndrome, Fatty Acid Synthesis and Prostate Cancer
代谢综合征、脂肪酸合成和前列腺癌
- 批准号:
8111906 - 财政年份:2008
- 资助金额:
$ 40.87万 - 项目类别:
Molecular Link Between Metabolic Syndrome and Prostate Cancer
代谢综合征与前列腺癌之间的分子联系
- 批准号:
8761515 - 财政年份:2008
- 资助金额:
$ 40.87万 - 项目类别:
相似海外基金
University of Aberdeen and Vertebrate Antibodies Limited KTP 23_24 R1
阿伯丁大学和脊椎动物抗体有限公司 KTP 23_24 R1
- 批准号:
10073243 - 财政年份:2024
- 资助金额:
$ 40.87万 - 项目类别:
Knowledge Transfer Partnership
Role of Natural Antibodies and B1 cells in Fibroproliferative Lung Disease
天然抗体和 B1 细胞在纤维增生性肺病中的作用
- 批准号:
10752129 - 财政年份:2024
- 资助金额:
$ 40.87万 - 项目类别:
CAREER: Next-generation protease inhibitor discovery with chemically diversified antibodies
职业:利用化学多样化的抗体发现下一代蛋白酶抑制剂
- 批准号:
2339201 - 财政年份:2024
- 资助金额:
$ 40.87万 - 项目类别:
Continuing Grant
Isolation and characterisation of monoclonal antibodies for the treatment or prevention of antibiotic resistant Acinetobacter baumannii infections
用于治疗或预防抗生素耐药鲍曼不动杆菌感染的单克隆抗体的分离和表征
- 批准号:
MR/Y008693/1 - 财政年份:2024
- 资助金额:
$ 40.87万 - 项目类别:
Research Grant
Developing first-in-class aggregation-specific antibodies for a severe genetic neurological disease
开发针对严重遗传神经系统疾病的一流聚集特异性抗体
- 批准号:
10076445 - 财政年份:2023
- 资助金额:
$ 40.87万 - 项目类别:
Grant for R&D
Discovery of novel nodal antibodies in the central nervous system demyelinating diseases and elucidation of the mechanisms through an optic nerve demyelination model
发现中枢神经系统脱髓鞘疾病中的新型节点抗体并通过视神经脱髓鞘模型阐明其机制
- 批准号:
23K14783 - 财政年份:2023
- 资助金额:
$ 40.87万 - 项目类别:
Grant-in-Aid for Early-Career Scientists
Elucidation of the mechanisms controlling the physicochemical properties and functions of supercharged antibodies and development of their applications
阐明控制超电荷抗体的理化性质和功能的机制及其应用开发
- 批准号:
23KJ0394 - 财政年份:2023
- 资助金额:
$ 40.87万 - 项目类别:
Grant-in-Aid for JSPS Fellows
Role of antibodies in hepatitis E virus infection
抗体在戊型肝炎病毒感染中的作用
- 批准号:
10639161 - 财政年份:2023
- 资助金额:
$ 40.87万 - 项目类别:
Defining the protective or pathologic role of antibodies in Post-Ebola Syndrome
定义抗体在埃博拉后综合症中的保护或病理作用
- 批准号:
10752441 - 财政年份:2023
- 资助金额:
$ 40.87万 - 项目类别:
Human CMV monoclonal antibodies as therapeutics to inhibit virus infection and dissemination
人 CMV 单克隆抗体作为抑制病毒感染和传播的治疗药物
- 批准号:
10867639 - 财政年份:2023
- 资助金额:
$ 40.87万 - 项目类别: